These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19751735)

  • 1. Role of placental growth factor in mesenteric neoangiogenesis in a mouse model of portal hypertension.
    Van Steenkiste C; Geerts A; Vanheule E; Van Vlierberghe H; De Vos F; Olievier K; Casteleyn C; Laukens D; De Vos M; Stassen JM; Carmeliet P; Colle I
    Gastroenterology; 2009 Dec; 137(6):2112-24.e1-6. PubMed ID: 19751735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats.
    Angermayr B; Fernandez M; Mejias M; Gracia-Sancho J; Garcia-Pagan JC; Bosch J
    Gut; 2007 Apr; 56(4):560-4. PubMed ID: 16854998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats.
    Fernandez M; Mejias M; Garcia-Pras E; Mendez R; Garcia-Pagan JC; Bosch J
    Hepatology; 2007 Oct; 46(4):1208-17. PubMed ID: 17654489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats.
    Huang HC; Wang SS; Hsin IF; Chang CC; Lee FY; Lin HC; Chuang CL; Lee JY; Hsieh HG; Lee SD
    Hepatology; 2012 Jul; 56(1):248-58. PubMed ID: 22290687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2'-Hydroxyflavanone ameliorates mesenteric angiogenesis and portal-systemic collaterals in rats with liver fibrosis.
    Hsin IF; Lee JY; Huo TI; Lee FY; Huang HC; Hsu SJ; Wang SS; Ho HL; Lin HC; Lee SD
    J Gastroenterol Hepatol; 2016 May; 31(5):1045-51. PubMed ID: 26474184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study.
    Geerts AM; De Vriese AS; Vanheule E; Van Vlierberghe H; Mortier S; Cheung KJ; Demetter P; Lameire N; De Vos M; Colle I
    Liver Int; 2006 Sep; 26(7):889-98. PubMed ID: 16911473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis and portal-systemic collaterals in portal hypertension.
    Gana JC; Serrano CA; Ling SC
    Ann Hepatol; 2016; 15(3):303-13. PubMed ID: 27049484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin reverses major portal hypertension-related derangements in rats with liver cirrhosis and diabetes.
    Hsin IF; Huang HC; Chang CC; Hsu SJ; Lee FY; Huo TI; Chuang CL; Hou MC; Lee SD
    Clin Sci (Lond); 2018 Nov; 132(22):2391-2405. PubMed ID: 30348829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined administration of propranolol + AG490 offers better effects on portal hypertensive rats with cirrhosis.
    Wang D; Wang Q; Yin J; Dong R; Wang Q; Du X; Lu J
    J Gastroenterol Hepatol; 2016 May; 31(5):1037-44. PubMed ID: 26487394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling.
    Reiberger T; Payer BA; Schwabl P; Hayden H; Horvatits T; Jäger B; Hummel T; Mitterhauser M; Trauner M; Fuhrmann V; Angermayr B; Peck-Radosavljevic M;
    Liver Int; 2013 Apr; 33(4):561-8. PubMed ID: 23331709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.
    Mejias M; Garcia-Pras E; Tiani C; Miquel R; Bosch J; Fernandez M
    Hepatology; 2009 Apr; 49(4):1245-56. PubMed ID: 19137587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats.
    Schwabl P; Payer BA; Grahovac J; Klein S; Horvatits T; Mitterhauser M; Stift J; Boucher Y; Trebicka J; Trauner M; Angermayr B; Fuhrmann V; Reiberger T; Peck-Radosavljevic M
    J Hepatol; 2014 Jun; 60(6):1135-42. PubMed ID: 24530596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycyrrhizin Attenuates Portal Hypertension and Collateral Shunting via Inhibition of Extrahepatic Angiogenesis in Cirrhotic Rats.
    Pun CK; Huang HC; Chang CC; Chuang CL; Yen CH; Hsu SJ; Lee FY; Hou MC; Huang YH
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glytan decreases portal pressure via mesentery vasoconstriction in portal hypertensive rats.
    Du QH; Han L; Jiang JJ; Xu Y; Li WH; Li PT; Wang XY; Jia X
    World J Gastroenterol; 2014 Nov; 20(44):16674-82. PubMed ID: 25469036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Green tea polyphenol decreases the severity of portosystemic collaterals and mesenteric angiogenesis in rats with liver cirrhosis.
    Hsu SJ; Wang SS; Hsin IF; Lee FY; Huang HC; Huo TI; Lee WS; Lin HC; Lee SD
    Clin Sci (Lond); 2014 May; 126(9):633-44. PubMed ID: 24063570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice.
    Fernandez M; Vizzutti F; Garcia-Pagan JC; Rodes J; Bosch J
    Gastroenterology; 2004 Mar; 126(3):886-94. PubMed ID: 14988842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model.
    Heindryckx F; Coulon S; Terrie E; Casteleyn C; Stassen JM; Geerts A; Libbrecht L; Allemeersch J; Carmeliet P; Colle I; Van Vlierberghe H
    J Hepatol; 2013 Feb; 58(2):319-28. PubMed ID: 23046674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats.
    Fernandez M; Mejias M; Angermayr B; Garcia-Pagan JC; Rodés J; Bosch J
    J Hepatol; 2005 Jul; 43(1):98-103. PubMed ID: 15893841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats.
    Coch L; Mejias M; Berzigotti A; Garcia-Pras E; Gallego J; Bosch J; Mendez R; Fernandez M
    Hepatology; 2014 Aug; 60(2):633-47. PubMed ID: 24390792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aliskiren reduces portal pressure in portal hypertensive rats.
    Chang CC; Lee WS; Huang HC; Lee FY; Wang SS; Lin HC; Nong JY; Lee SD
    Eur J Clin Invest; 2012 May; 42(5):526-33. PubMed ID: 22023532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.